Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome

Clin Ther. 2021 Jul;43(7):1278-1280. doi: 10.1016/j.clinthera.2021.05.014. Epub 2021 Jun 27.

Authors

Isabelle J Pouliquen¹, Daren Austin², Jonathan Steinfeld³, Steven W Yancey⁴

Affiliations

¹ GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom. Electronic address: [email protected].
² GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom.
³ GSK, Philadelphia, PA, USA.
⁴ GSK, Research Triangle Park, NC, USA.

PMID: 34187697
DOI: 10.1016/j.clinthera.2021.05.014

No abstract available

Keywords: EGPA; HES; biologics; blood eosinophils; dosing regimen justification; mepolizumab.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Churg-Strauss Syndrome* / diagnosis
Churg-Strauss Syndrome* / drug therapy
Eosinophils
Granulomatosis with Polyangiitis* / diagnosis
Granulomatosis with Polyangiitis* / drug therapy
Humans
Hypereosinophilic Syndrome* / diagnosis
Hypereosinophilic Syndrome* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
mepolizumab